Theravance Biopharma (TBPH) Cash & Equivalents (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Cash & Equivalents data on file, last reported at $288.1 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 160.46% year-over-year to $288.1 million in Q1 2026; TTM through Mar 2026 was $288.1 million, a 160.46% increase from a year earlier, with the FY2025 full-year figure at $167.8 million, up 343.97% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $288.1 million, up from $167.8 million in the prior quarter.
• Over the last five years, Cash & Equivalents for TBPH reached as high as $418.5 million in Q3 2022 and fell as low as $23.4 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $146.3 million across 5 years, with a median of $105.6 million in 2023.
• Across the five-year window, Cash & Equivalents slumped 86.74% in 2023 and jumped 647.6% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $298.2 million in 2022, then slumped by 86.74% to $39.5 million in 2023, then declined by 4.42% to $37.8 million in 2024, then soared by 343.97% to $167.8 million in 2025, then jumped by 71.69% to $288.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $288.1 million in Q1 2026, $167.8 million in Q4 2025, and $174.8 million in Q3 2025.